DK0766512T3 - Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler - Google Patents

Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler

Info

Publication number
DK0766512T3
DK0766512T3 DK95924631T DK95924631T DK0766512T3 DK 0766512 T3 DK0766512 T3 DK 0766512T3 DK 95924631 T DK95924631 T DK 95924631T DK 95924631 T DK95924631 T DK 95924631T DK 0766512 T3 DK0766512 T3 DK 0766512T3
Authority
DK
Denmark
Prior art keywords
herpes simplex
simplex virus
replication competent
competent herpes
neoplastic cells
Prior art date
Application number
DK95924631T
Other languages
Danish (da)
English (en)
Inventor
Toshihiro Mineta
Robert L Martuza
Samuel D Rabkin
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of DK0766512T3 publication Critical patent/DK0766512T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95924631T 1994-06-23 1995-06-23 Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler DK0766512T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/264,581 US5585096A (en) 1994-06-23 1994-06-23 Replication-competent herpes simplex virus mediates destruction of neoplastic cells
PCT/US1995/007858 WO1996000007A1 (en) 1994-06-23 1995-06-23 Replication-competent herpes simplex virus mediates destruction of neoplastic cells

Publications (1)

Publication Number Publication Date
DK0766512T3 true DK0766512T3 (da) 2009-02-09

Family

ID=23006703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95924631T DK0766512T3 (da) 1994-06-23 1995-06-23 Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler

Country Status (9)

Country Link
US (1) US5585096A (ja)
EP (2) EP0766512B1 (ja)
JP (1) JP3726841B2 (ja)
AT (2) ATE409751T1 (ja)
AU (2) AU679644B2 (ja)
CA (1) CA2193491C (ja)
DE (2) DE69535851D1 (ja)
DK (1) DK0766512T3 (ja)
WO (1) WO1996000007A1 (ja)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US6770274B1 (en) * 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
CA2132976C (en) 1992-03-31 2003-12-30 Bernard Roizman Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US6699468B1 (en) * 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
ES2264136T3 (es) * 1995-02-21 2006-12-16 Cantab Pharmaceuticals Research Limited Preparaciones virales, vectores, inmunogenos y sus vacunas.
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
IL118942A (en) * 1995-07-27 2002-09-12 American Cyanamid Co Nonviolent viruses used as killers - tumors and vaccines
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
CA2234060A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
AU1550797A (en) * 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
JPH1087503A (ja) * 1996-09-06 1998-04-07 Nippon Chem Res Kk 神経系腫瘍細胞のアポトーシス剤
GB9704046D0 (en) * 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
CA2284611A1 (en) 1997-03-27 1998-10-01 Richard B. Pyles Replication-competent herpes simplex viruses
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
DE69838340T2 (de) 1997-10-09 2008-05-21 Wellstat Biologics Corp. Behandlung von neoplasmen mit interferonempfindlichen, klonalen viren
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US20040151697A1 (en) * 1998-01-08 2004-08-05 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
WO1999045783A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
US6602499B1 (en) 1998-04-30 2003-08-05 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
US7186409B2 (en) * 1998-08-14 2007-03-06 The Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
DK1115290T3 (da) * 1998-10-01 2009-06-22 Univ Southern California Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf
EP1141338A4 (en) * 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES
ES2310382T3 (es) * 1999-02-05 2009-01-01 Arch Development Corporation Virus herpes modificado geneticamente para el tratamiento de tumores.
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
HUP0302278A3 (en) * 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
AU781219B2 (en) * 1999-08-31 2005-05-12 General Hospital Corporation, The Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
CA2388807C (en) * 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
WO2001053505A2 (en) 2000-01-21 2001-07-26 Biovex Limited Herpes virus strains for gene therapy
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
AR028040A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
CA2409932A1 (en) * 2000-06-01 2001-12-06 Sloan-Kettering Institute For Cancer Research Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
WO2002045431A2 (en) 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
US7749745B2 (en) 2001-03-27 2010-07-06 Georgetown University Viral vectors and their use in therapeutic methods
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
US7758893B2 (en) * 2001-07-27 2010-07-20 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
ES2208051B1 (es) * 2002-01-24 2005-08-16 Consejo Sup. Investig. Cientificas Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
US20050255085A1 (en) * 2002-03-01 2005-11-17 Yuman Fong Prevention of recurrence and metastasis of cancer
AU2003258060B2 (en) * 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
WO2003083105A1 (fr) * 2002-03-28 2003-10-09 Medicalseed Co., Ltd. Traitement et prevention de l'angiostenose
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
JP2005073653A (ja) * 2003-09-02 2005-03-24 Keio Gijuku ヒトグリオーマ治療に有用な変異ｈｓｖベクター
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20080206199A1 (en) * 2005-07-01 2008-08-28 The Uab Research Foundation Chimeric Herpes Viruses and Uses Thereof
WO2008141151A2 (en) * 2007-05-09 2008-11-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
US8765444B2 (en) * 2009-07-15 2014-07-01 The Board Of Trustees Of The University Of Illinois Compositions and methods using herpes simplex virus
GB201101167D0 (en) * 2011-01-22 2011-03-09 Renishaw Plc Convection enhanced delivery apparatus and method
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
AU2015362687B2 (en) 2014-12-18 2021-12-09 Amgen Inc. Stable frozen herpes simplex virus formulation
CN110461346A (zh) 2017-03-15 2019-11-15 美国安进公司 溶瘤病毒单独或与检查点抑制剂组合用于治疗癌症的用途
WO2019028316A1 (en) 2017-08-03 2019-02-07 Amgen Inc. INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT
AR112405A1 (es) 2017-08-07 2019-10-23 Amgen Inc Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas
SG11202101581RA (en) 2017-08-09 2021-03-30 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
AR112797A1 (es) 2017-09-08 2019-12-11 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos
WO2019108777A1 (en) 2017-11-29 2019-06-06 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
TW202039835A (zh) 2018-12-27 2020-11-01 美商安進公司 凍乾病毒配製物
KR20210135532A (ko) 2019-03-05 2021-11-15 암젠 인크 암 치료를 위한 종양 용해 바이러스의 용도
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3122669A1 (de) * 1980-06-12 1982-02-11 Asta-Werke Ag, Chemische Fabrik, 4800 Bielefeld "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2"
NL9001828A (nl) * 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication

Also Published As

Publication number Publication date
AU679644B2 (en) 1997-07-03
EP0766512A4 (en) 1999-04-14
US5585096A (en) 1996-12-17
EP0766512B1 (en) 2008-10-01
EP1428887A1 (en) 2004-06-16
DE69535584T2 (de) 2008-05-15
ATE371036T1 (de) 2007-09-15
JPH10501990A (ja) 1998-02-24
EP1428887B1 (en) 2007-08-22
ATE409751T1 (de) 2008-10-15
CA2193491C (en) 2010-04-06
EP0766512A1 (en) 1997-04-09
AU3988897A (en) 1998-01-08
JP3726841B2 (ja) 2005-12-14
AU2906095A (en) 1996-01-19
CA2193491A1 (en) 1996-01-04
DE69535851D1 (de) 2008-11-13
WO1996000007A1 (en) 1996-01-04
DE69535584D1 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
DK0766512T3 (da) Replikationskompetent herpes simplex-virus formidler destruktion af neoplastiske celler
ATE342724T1 (de) Verwendung von herpes-vektoren zur tumortherapie
DE69106237D1 (de) Antimigräne Alkoxypyrimidinderivate.
KR950010236U (ko) 리드핀의 소켓
ES2086516T3 (es) Protesis de articulacion de la rodilla.
EP0901780A4 (ja)
ITTV930002A1 (it) Struttura di pattino perfezionato
DE69133022T2 (de) Viral verursachte Zerstörung von Neoplastzellen
GB9415320D0 (en) Cancer treatment
DK0625195T3 (da) Behandling af centralnervesystemet med genetisk modificerede celler
AU558175B2 (en) Sunglasses with an adjustable nose piece
FI875072A (fi) Ryggsaeck.
MA23057A1 (fr) Article absorbant ayant un moyen de fixation adhesif auto-degageable.
MA23056A1 (fr) Article absorbant ayant une piece d'adhesif susceptible d'un degagement
USD274094S (en) Tibial positioning/fixation jig for the implanation of a prosthetic knee
USD274264S (en) Inflatable splint
ITBZ910020A1 (it) Procedimento per la realizzazione di un accumulatore termico e accumulatore termico per l'attuazione del procedimento.
MX7221E (es) Procedimiento para la preparacion de derivados de los acidos 2 o 4 tiazolidincarboxilicos 3-acil sustituidos
ES2061722T3 (es) Derivados de fenantridina, procedimiento para su obtencion y agentes para la realizacion del procedimiento.
RU93015154A (ru) Радиопротектор
IT1302979B1 (it) Trave per un dirigibile
SE8403395D0 (sv) Skap, forsett med veggar av stalplat e d
IT8234029V0 (it) Rete da letto ortopedica, a una odue piazze, ad elasticita'bilanciata con inserimento di elementi trasversali flessibili e compensazione della trazione sul telaio portante.
DE3583741D1 (de) Kniegelenk-endoprothese.